3′ Equatorial Fluorine Neuraminidase Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current neuraminidase inhibitors, such as oseltamivir, face challenges with the emergence of drug-resistant viral strains, particularly against influenza subtypes like N1 and N2, where mutations like H275Y and R292K reduce their effectiveness, necessitating the development of new inhibitors that maintain potency against mutant strains.
Innovation Solution
Compounds with a 3′ equatorial fluorine configuration, like FeqGuDFSA and FeqAmDFSA, are developed, which exhibit prolonged inhibition of neuraminidase activity and demonstrate enhanced potency against mutant viral strains compared to their corresponding stereoisomers with a 3′ axial fluorine configuration, incorporating a guanidinium or ammonium substituent at the C-4 position for increased affinity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional neuraminidase inhibitors like oseltamivir are used, then they show initial effectiveness against influenza viruses, but drug-resistant viral strains emerge that reduce their effectiveness
Solution Approach 1:
The patent changes the stereochemical configuration parameter of the fluorine substituent at the 3' position from axial to equatorial. This parameter change fundamentally alters the compound's interaction with the neuraminidase active site, particularly with the E119 residue, thereby maintaining effectiveness against mutant strains including those with the E119V mutation that confers resistance to conventional inhibitors.
Solution Approach 2:
The patent introduces local quality changes by specifically modifying the 3' position fluorine configuration while maintaining other structural features. The equatorial fluorine at C-3' creates specific local interactions with the enzyme active site that differ from axial configuration, providing enhanced binding characteristics that overcome resistance mechanisms in mutant viral strains.
2Reliability
If compounds with 3' axial fluorine configuration are used, then they show certain neuraminidase inhibition activity, but they fail to maintain potency against mutant viral strains
Solution Approach 1:
The patent applies parameter change by inverting the stereochemical configuration at the 3' position from axial to equatorial. This single parameter change produces compounds that maintain potency against mutant strains including H275Y, R292K, and E119V, demonstrating enhanced adaptability to resistant viral variants compared to axial configurated compounds.
Solution Approach 2:
The patent employs inversion by switching the fluorine configuration from the conventional axial orientation to the equatorial orientation. This inverted configuration unexpectedly provides superior activity against resistant strains, including those with mutations that confer resistance to axially-configured compounds and conventional inhibitors like oseltamivir.
3Reliability
If new inhibitor compounds are developed to maintain potency against mutant strains, then resistance issues are addressed, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent achieves enhanced efficacy against resistant viruses through a localized modification - changing only the 3' fluorine configuration to equatorial - while maintaining the overall sialic acid analog structure. This minimal structural change avoids significant increases in compound complexity while delivering improved reliability against mutant strains.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds show a significant increase in maintaining potency against resistant viral strains, with FeqGuDFSA and FeqAmDFSA demonstrating up to 100-fold better maintenance of efficacy against mutant viruses, offering a potential solution to the resistance issues faced with existing neuraminidase inhibitors.
Implementation Method 1
Fluorinated sugar derivatives with (reactive) fluoride leaving groups have been shown to be inhibitors of a range of 'retaining' glycosidases and function via formation of particularly stable glycosyl-enzyme intermediates
Implementation Method 2
Specificity for the influenza enzyme over other NAs, along with additional affinity, was provided by incorporation of a guanidinium or ammonium substituent at the position corresponding to C-4 of the natural substrate to interact with a highly conserved anionic pocket at that location in the active site
Data Source
AI summary
Equatorial 2,3-fluorinated glycosides compounds of formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza, the methods for their preparation, and their pharmaceutical compositions are provided. The therapeutic effect is achieved via inhibition of viral neuraminidases.